Loading…
Loading…
See exactly how RXL's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RXL and 80,000+ other tickers.
ProShares Trust - ProShares Ultra Health Care is an exchange traded fund launched and managed by ProShare Advisors LLC. The fund invests in public equity markets of the United States. The fund invests through derivatives in stocks of companies operating across health care equipments, providers, services, technology, biotechnology; pharmaceuticals, and life sciences tools & service sectors. The fund uses derivatives such as swaps to create its portfolio. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track 2x the daily performance…
ProShares Ultra Health Care (NYSEARCA:RXL - Get Free Report) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 931 shares, a decline of 13.7% from the March 15th total of 1,079 shares. Based on an average trading volume of 9,353 shares, the short-interest
ProShares Ultra Health Care (NYSEARCA:RXL - Get Free Report)'s stock price crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $49.61 and traded as low as $46.08. ProShares Ultra Health Care shares last traded at $46.16, with a volume of 7,180 shares. ProShares Ultra Health
ProShares Ultra Health Care (NYSEARCA:RXL - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $48.97 and traded as high as $52.22. ProShares Ultra Health Care shares last traded at $51.75, with a volume of 3,556 shares. ProShares
With a new year comes the opportunity to make changes, and that's what ProShares has done by swapping benchmarks on 23 ETFs, largely focused on their inverse and leveraged strategies.
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.